Literature DB >> 2016128

Pericyte changes in branch retinal vein occlusion.

I H Wallow1, C D Bindley, K L Linton, D Rastegar.   

Abstract

The model of experimental branch vein occlusion (BVO) in the monkey offers the opportunity to examine retinal capillaries under stress. Electron microscopic morphometry was done on 812 capillaries of 13 eyes of cynomolgus monkeys, comparing 579 capillary collaterals of 9 BVO eyes with 233 normal capillaries of 4 control eyes. The tissue underwent the myosin subfragment-1 technique to decorate and quantify bundles of actin filaments in capillary pericytes. The duration of BVO was 2-48 months. Capillary collaterals of BVO eyes had an enlarged caliber, endothelial hyperplasia, and pericyte hypertrophy, but no proportional increase in basement membrane area. Collaterals near the inner plexiform layer (IPL) had a greater wall thickness, pericyte coverage, and actin coverage than collaterals near the outer plexiform layer (OPL). Pericyte hypertrophy was proportionate to caliber increase in OPL vessels and exceeded caliber increase only in IPL vessels. Actin coverage was proportional with the vessel dilation and size of pericyte cytoplasm in all vessels. These findings indicate that capillary collaterals in BVO are not equipped morphologically for an increased regulatory role in microvascular flow beyond their normal function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016128

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  2 in total

1.  Haemorheology in patients with branch retinal vein occlusion with and without risk factors.

Authors:  A Remky; O Arend; F Jung; H Kiesewetter; M Reim; S Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

2.  Light and electron microscopic studies on human retinal blood vessels of patients with sclerosis and hypertension.

Authors:  Tsuyoshi Kimura; Atsushi Mizota; Naoya Fujimoto; Yoshihiko Tsuyama
Journal:  Int Ophthalmol       Date:  2007-02-09       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.